Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management
Is surgery still the best answer for basal cell carcinoma?
Vault Navigation
Is surgery still the best answer for basal cell carcinoma?
What are the effects of medical and surgical interventions for basal cell carcinoma in immunocompetent adults?
Surgery remains the most effective treatment modality for basal cell carcinoma (BCC) in terms of reducing recurrences, and there may be a slightly reduced recurrence rate with Mohs micrographic surgery compared with surgical excision (SE). Regarding improvement of participant and observer‐rated cosmetic outcomes, there may be little to no difference between Mohs micrographic surgery and SE (low‐certainty evidence). Radiotherapy is effective but probably worse than surgery in terms of the number of good cosmetic outcomes (moderate‐certainty evidence); therefore, it is best reserved for tumours not amenable to surgery. Radiotherapy may also lead to increased recurrence compared with SE (low‐certainty evidence).
Non‐surgical treatments are less effective, but the evidence suggests recurrence rates are acceptable, and they are important options to offer patients. Of the non‐surgical options, imiquimod has the best evidence to support its efficacy. It probably results in more recurrences than SE (moderate‐certainty evidence), and there is probably little to no difference in the number of participant‐rated good/excellent cosmetic outcomes (low‐certainty evidence). However, imiquimod may increase the number of observer‐rated good/excellent cosmetic outcomes compared with SE (low‐certainty evidence).
Moderate‐certainty evidence indicates imiquimod probably leads to fewer recurrences than methyl aminolevulinate photodynamic therapy (MAL‐PDT), and there is probably little to no difference in observer‐rated good/excellent cosmetic outcomes between these treatments (participant‐rated cosmetic outcomes were not measured). MAL‐PDT may result in more recurrences at 3 years than SE (low‐certainty evidence; no useable data at 5 years) but probably increases the number of good/excellent cosmetic results (moderate‐certainty evidence).
Adverse effects with surgical interventions include wound infections, graft necrosis and post‐operative bleeding. Local adverse effects, such as itching, weeping, pain and redness, occur frequently with non‐surgical interventions. Treatment‐related adverse effects resulting in study modification or withdrawal occurred with imiquimod and MAL‐PDT.
Most studies were performed on low‐risk histological BCCs located on low‐risk sites, and the results of which are probably not applicable to high‐risk tumours. Only 4 studies looked at high‐risk histological subtypes, and 3 studies looked at BCCs at high‐risk facial sites. More studies or subgroup analyses are required for morphoeic tumours.
BCC is a common cancer and the worldwide incidence is increasing. Although rarely fatal, BCC is associated with significant morbidity and costs. First‐line treatment is usually SE, but alternatives are available.
Thomson J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2020, Issue 11. Art. No.: CD003412. DOI: 10.1002/14651858.CD003412.pub3. This review contains 52 trials with a total of 6690 participants.